Clinical Trials Logo

Uveitis clinical trials

View clinical trials related to Uveitis.

Filter by:

NCT ID: NCT01837056 Completed - Uveitis Clinical Trials

Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis

Start date: January 2011
Phase: N/A
Study type: Observational [Patient Registry]

Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis - serum antibody to T. gondii and T. canis - PCR with peripheral blood for T. gondii and T. canis - PCR with aqueous humor for T. gondii and T. canis - Clinical manifestation of patient with uveitis

NCT ID: NCT01829295 Completed - Uveitis Clinical Trials

Methotrexate and Mycophenolate Mofetil for UVEITIS

FAST
Start date: August 2013
Phase: Phase 3
Study type: Interventional

In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative effectiveness trial.

NCT ID: NCT01791192 Withdrawn - Clinical trials for Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Study of FTY720 in Patients With Uveitis

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

NCT ID: NCT01789320 Completed - Uveitis Clinical Trials

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

NCT ID: NCT01781936 Completed - Clinical trials for Uveitis Affecting the Posterior Segment

Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis

Iluvien
Start date: June 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the tolerability, safety, and benefits of an investigational drug,Fluocinolone Acetonide Intravitreal Insert (FA-i), in people who have posterior uveitis. The study drug, Fluocinolone Acetonide, is currently used in a surgical implant, Retisert, which is approved by the U.S. Food and Drug Administration (FDA) to treat non-infectious posterior uveitis . The study drug is able to be inserted in an ophthalmology (eye) clinic; whereas Retisert must be surgically implanted in the Operating Room. Initially, this was a 2-dose randomized pilot study. However, the study was modified to include only the 0.2 ug/day implant.

NCT ID: NCT01747538 Terminated - Uveitis Clinical Trials

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

EYEGUARD™-C
Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.

NCT ID: NCT01746537 Recruiting - Uveitis Clinical Trials

Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography

ATAC
Start date: June 2012
Phase:
Study type: Observational

A prospective, observational, case series investigating the feasibility of utilizing OCT scans of the anterior chamber of eyes with uveitis.

NCT ID: NCT01717170 Active, not recruiting - Posterior Uveitis Clinical Trials

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

STOP-Uveitis
Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or panuveitis.

NCT ID: NCT01694186 Completed - Clinical trials for Non-Infectious Uveitis

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

FAI
Start date: August 2, 2013
Phase: Phase 3
Study type: Interventional

A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.

NCT ID: NCT01684345 Terminated - Uveitis Clinical Trials

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

EYEGUARD™-A
Start date: August 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.